  | Reigstad, A., Herdlevær, C. F., Rigg, E., Hoang, T., Bjørnstad, O. V., Aasen, S. N., Preis, J. R., Haan, C., Sundstrøm, T., & Thorsen, F. (2022). CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. PLoS ONE. doi:10.1371/journal.pone.0273711  Peer Reviewed verified by ORBi |
 | Kirchmeyer, M., Servais, F., Ginolhac, A., Nazarov, P. V., Margue, C., Philippidou, D., Nicot, N., Behrmann, I., Haan, C., & Kreis, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011 Peer Reviewed verified by ORBi |
 | Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (15 February 2019). Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta - Reviews on Cancer, 1871 (2), 313-322. doi:10.1016/j.bbcan.2019.02.002 Peer Reviewed verified by ORBi |
 | Margue, C., Philippidou, D., Kozar, I., Cesi, G., Felten, P., Kulms, D., Letellier, E., Haan, C., & Kreis, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x Peer Reviewed verified by ORBi |
 | Servais, F., Kirchmeyer, M., Hamdorf, M., Minoungou, W. N., Rose-John, S., Kreis, S., Haan, C., & Behrmann, I. (2019). Modulation of the IL-6 signaling pathway in liver cells by miRNAs targeting gp130, JAK1 and/or STAT3. Molecular Therapy: Nucleic Acids, 16, 419-433. doi:10.1016/j.omtn.2019.03.007 Peer Reviewed verified by ORBi |
 | Cesi, G., Philippidou, D., Kozar, I., Kim, Y. J., Bernardin, F., Van Niel, G., Wienecke-Baldacchino, A., Felten, P., Letellier, E., Dengler, S., Nashan, D., Haan, C., & Kreis, S. (2018). A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, (17:145). doi:10.1186/s12943-018-0886-x Peer Reviewed verified by ORBi |
 | Rolvering, C., Zimmer, A. D., Ginolhac, A., Margue, C., Kirchmeyer, M., Servais, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., Kreis, S., Haan, S., Behrmann, I., & Haan, C. (2018). The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by a-PD-L1 or a-IL6 antibodies. Journal of Leukocyte Biology, 104, 969-985. doi:10.1002/JLB.MA1217-495R Peer Reviewed verified by ORBi |
 | Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (08 June 2017). ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer, 8 (june). doi:10.1186/s12943-017-0667-y Peer Reviewed verified by ORBi |
 | Rolvering, C., Zimmer, A., Kozar, I., Hermanns, Letellier, E., Vallar, L., Nazarov, P., Nicot, N., Ginolhac, A., Haan, S., Behrmann, I., & Haan, C. (2017). Crosstalk between different family members: IL27 recapitulates IFNγ responses in HCC cells, but is inhibited by IL6-type cytokines. BBA Molecular Cell Research, 516-526. doi:10.1016/J.BBAMCR.2016.12.006 Peer Reviewed verified by ORBi |
  | Bongartz, H., Hessenkemper, W., Müller, C., Fensky, M., Fritsch, J., Mandel, K., Behrmann, I., Haan, C., Fischer, T., Feller, S. M., & Schaper, F. (2017). The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617Fpositive cells and mediates proliferation of human erythroleukaemia cells. Cellular Signalling, 35, 37-47. doi:10.1016/j.cellsig.2017.03.021 Peer reviewed |
 | Zimmer, A. D., Walbrecq, G., Kozar, I., Behrmann, I., & Haan, C. (2016). Phosphorylation of the PDH complex precedes HIF-1-mediated effects and PDK1 upregulation during the first hours of hypoxic treatment in HCC cells. Hypoxia, 4, 135-145. doi:10.2147/HP.S99044 Peer reviewed |
 | Battello, N., Zimmer, A. D., Goebel, C., Dong, X., Behrmann, I., Haan, C., Hiller, K., & Wegner, A. (2016). The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer and Metabolism, 4, 3. doi:10.1186/s40170-016-0141-0 Peer Reviewed verified by ORBi |
 | Haan, S., Bahlawane, C., Wang, J., Nazarov, P. V., Muller, A., Eulenfeld, R., Haan, C., Rolvering, C., Vallar, L., Satagopam, V., Sauter, T., & Wiesinger, M. (2015). The oncogenic FIP1L1-PDGFRalpha fusion protein displays skewed signaling properties compared to its wild-type PDGFRalpha counterpart. JAK-STAT, 4 (1), 1062596. doi:10.1080/21623996.2015.1062596 Peer reviewed |
 | Servais, F., Kirchmeyer, M., Hamdorf, M., Haan, C., Casper, M., Lammert, F., Nazarov, P., Vallar, L., Kreis, S., & Behrmann, I. (2015). ID: 194: Role of microRNAs in signal transduction pathways of the inflammatory cytokine Interleukin-6: Relevance for liver diseases. Cytokine, 76 (1), 99. doi:10.1016/j.cyto.2015.08.198 Peer reviewed |
 | Gäbler, K., Behrmann, I., & Haan, C. (2013). JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT, 2 (3), 25025. doi:10.4161/jkst25025 Peer reviewed |
 | Wolf, A., Eulenfeld, R., Gäbler, K., Rolvering, C., Haan, S., Behrmann, I., Denecke, B., Haan, C., & Schaper, F. (2013). JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. JAK-STAT, 2 (3), 24574. doi:10.4161/jkst.24574 Peer reviewed |
 | Gäbler, K., Rolvering, C., Kaczor, J., Eulenfeld, R., Méndez, S. A., Berchem, G., Palissot, V., Behrmann, I., & Haan, C. (2013). Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. Journal of Cellular and Molecular Medicine, 17 (2), 265-276. doi:10.1111/jcmm.12005 Peer reviewed |
 | Haan, C., & Haan, S. (2013). Co-immunoprecipitation protocol to investigate cytokine receptor-associated proteins, e.g., Janus kinases or other associated signaling proteins. Methods in Molecular Biology, 967, 21-38. doi:10.1007/978-1-62703-242-1_2 Peer reviewed |
 | Haan, S., & Haan, C. (2013). Detection of activated STAT species using electrophoretic mobility shift assay (EMSA) and potential pitfalls arising from the use of detergents. Methods in Molecular Biology, 967, 147-59. doi:10.1007/978-1-62703-242-1_10 Peer reviewed |
Haan, C., Ungureanu, D., Pekkala, T., Silvennoinen, O., & Haan, S. (2012). Regulation of JAKs: Insights gleaned from the functional protein domains. In T. Decker & M. Müller (Eds.), JAK-STAT Signaling – From Basics to Disease (pp. 5-25). Wien, Austria: Springer-Verlag. doi:10.1007/978-3-7091-0891-8_2 |
 | Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., & Zerwes, H.-G. (2011). Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chemistry and Biology, 18 (3), 314-323. doi:10.1016/j.chembiol.2011.01.012 Peer reviewed |
 | Vollmer, S., Haan, C., & Behrmann, I. (2010). Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochemical Pharmacology, 80 (12), 2066-2073. doi:10.1016/j.bcp.2010.07.015 Peer reviewed |
 | Haan, C., Behrmann, I., & Haan, S. (2010). Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Journal of Cellular and Molecular Medicine, 14 (3), 504-27. doi:10.1111/j.1582-4934.2010.01018.x Peer reviewed |
 | Haan, C., Kroy, D. C., Wüller, S., Sommer, U., Nöcker, T., Rolvering, C., Behrmann, I., Heinrich, P. C., & Haan, S. (2009). An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. Journal of Immunology, 182 (5), 2969-2977. doi:10.4049/jimmunol.0800572 Peer Reviewed verified by ORBi |
 | Hintzen, C., Haan, C., Tuckermann, J. P., Heinrich, P. C., & Hermanns, H. M. (2009). Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of Immunology, 181 (10), 7341-7349. doi:10.4049/jimmunol.181.10.7341 Peer Reviewed verified by ORBi |
 | Haan, S., Wuller, S., Kaczor, J., Rolvering, C., Nocker, T., Behrmann, I., & Haan, C. (2009). SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene, 28 (34), 3069-80. doi:10.1038/onc.2009.155 Peer Reviewed verified by ORBi |
 | Bender, H., Wiesinger, M., Nordhoff, C., Schoenherr, C., Haan, C., Ludwig, S., Weiskirchen, R., Kato, N., Heinrich, P. C., & Haan, S. (2009). Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology, 50 (2), 585-91. doi:10.1002/hep.22988 Peer Reviewed verified by ORBi |
 | Vollmer, S., Kappler, V., Kaczor, J., Flügel, D., Rolvering, C., Kato, N., Kietzmann, T., Behrmann, I., & Haan, C. (2009). Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology, 2009 (3). doi:10.1002/hep.22928 Peer Reviewed verified by ORBi |
Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann, I., & Haan, C. (2008). Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. Journal of Immunology, 180 (2), 998-1007. doi:10.4049/jimmunol.180.2.998 Peer Reviewed verified by ORBi |
 | Haan, C., & Behrmann, I. (2007). A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of Immunological Methods, 318 (1-2), 11-9. doi:10.1016/j.jim.2006.07.027 Peer reviewed |
 | Kreis, S., Philippidou, D., Margue, C., Rolvering, C., Haan, C., Dumoutier, L., Renauld, J.-C., & Behrmann, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300 Peer Reviewed verified by ORBi |
 | Haan, C., Kreis, S., Margue, C., & Behrmann, I. (November 2006). Jaks and cytokine receptors - an intimate relationship. Biochemical Pharmacology, 72 (11), 1538-46. doi:10.1016/j.bcp.2006.04.013 Peer reviewed |
Haan, S., Keller, J. F., Behrmann, I., Heinrich, P. C., & Haan, C. (2005). Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cellular Signalling, 17 (12), 1542-50. doi:10.1016/j.cellsig.2005.03.010 Peer Reviewed verified by ORBi |
Radtke, S.* , Haan, S.* , Jörissen, A.* , Hermanns, H. M., Diefenbach, S., Smyczek, T., Schmitz-Vandeleur, H., Heinrich, P. C., Behrmann, I., & Haan, C. (2005). The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. Journal of Biological Chemistry, 280 (27), 25760-8. doi:10.1074/jbc.M500822200 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Behrmann, I., Smyczek, T., Heinrich, P. C., Schmitz-Van de Leur, H., Komyod, W., Giese, B., Muller-Newen, G., Haan, S., & Haan, C. (2004). Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. Journal of Biological Chemistry, 279 (34), 35486-93. doi:10.1074/jbc.M404202200 Peer Reviewed verified by ORBi |
Giese, B., Au-Yeung, C. K., Herrmann, A., Diefenbach, S., Haan, C., Küster, A., Wortmann, S. B., Roderburg, C., Heinrich, P. C., Behrmann, I., & Müller-Newen, G. (2003). Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. Journal of Biological Chemistry, 278 (40), 39205-13. doi:10.1074/jbc.M303347200 Peer Reviewed verified by ORBi |
Radtke, S., Hermanns, H. M., Haan, C., Schmitz-Van De Leur, H., Gascan, H., Heinrich, P. C., & Behrmann, I. (2002). Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. Journal of Biological Chemistry, 277 (13), 11297-305. doi:10.1074/jbc.M100822200 Peer Reviewed verified by ORBi |
Haan, C., Heinrich, P. C., & Behrmann, I. (2001). Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochemical Journal, 361 (Pt 1), 105-11. doi:10.1042/0264-6021:3610105 Peer Reviewed verified by ORBi |
Haan, C., Isharc, H., Hermanns, H. M., Schmitz-Van De Leur, H., Kerr, I. M., Heinrich, P. C., Grötzinger, J., & Behrmann, I. (2001). Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. Journal of Biological Chemistry, 276 (40), 37451-8. doi:10.1074/jbc.M106135200 Peer Reviewed verified by ORBi |
Haan, C., Hermanns, H. M., Heinrich, P. C., & Behrmann, I. (2001). A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. Biochemical Journal, 349 (Pt 1), 261-6. doi:10.1042/0264-6021:3490261 Peer Reviewed verified by ORBi |
Hermanns, H. M., Radtke, S., Haan, C., Schmitz-Van de Leur, H., Tavernier, J., Heinrich, P. C., & Behrmann, I. (2000). Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. Journal of Immunology, 163 (12), 6651-8. Peer Reviewed verified by ORBi |
Thiel, S., Sommer, U., Kortylewski, M., Haan, C., Behrmann, I., Heinrich, P. C., & Graeve, L. (2000). Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Letters, 470 (1), 15-9. doi:10.1016/S0014-5793(00)01276-X Peer Reviewed verified by ORBi |
Behrmann, I., Hermanns, H. M., Haan, C., Kortylewski, M., Radtke, S., Greiser, J. S., & Heinrich, P. C. (2000). Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. European Cytokine Network, 11 (3), 491-2. Peer Reviewed verified by ORBi |